TAYSHA GENE THERAPIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.4 USD | +2.56% |
|
-8.40% | +35.59% |
Presentation Operator MessageOperator (Operator)Good morning. Welcome to Taysha Gene Therapies...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.4
USD
Average target price
6.833
USD
Spread / Average Target
+184.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.59% | 438M | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Transcript : Taysha Gene Therapies, Inc. - Special Call